SUPRAX

Compare SUPRAX  to:
Compare
Compare
SUPRAX (Cefixime) 400mg tablets by Lupin Pharmaceuticals

Generic Name for SUPRAX

Cefixime 400mg; tabs.

Legal Classification:

Rx

Pharmacological Class for SUPRAX

Cephalosporin.

Manufacturer of SUPRAX

Lupin Pharmaceuticals, Inc.

Indications for SUPRAX

Susceptible infections, including pharyngitis, tonsillitis, acute bronchitis, acute exacerbation of chronic bronchitis; uncomplicated UTIs and cervical or urethral gonorrhea.

Adult dose for SUPRAX

400mg once daily or 200mg every 12 hrs. Gonorrhea: 400mg once. Renal impairment: CrCl 21–59mL/min: reduce dose by ¼; CrCl<20mL/min or dialysis: reduce dose by ½.

Children's dosing for SUPRAX

<6 months: not recommended. <50kg and 6 months–12yrs: 8mg/kg once daily or 4mg/kg every 12 hrs. >50kg or >12yrs: use adult dose. Renal impairment: CrCl 21–59mL/min: reduce dose by ¼; CrCl<20mL/min or dialysis: reduce dose by ½.

Also:

Warnings/Precautions for SUPRAX

Penicillin or other allergy. Renal impairment. History of GI disease. Labor and delivery. Pregnancy (Cat.B). Nursing mothers.

Interactions for SUPRAX

May potentiate carbamazepine, anticoagulants (eg, warfarin) (monitor). May cause false (+) Clinitest, direct Coomb's, nitroprusside test for ketones. Potentiated by probenecid.

Adverse Reactions for SUPRAX

GI upset, rash, drug fever, pruritus, headache, dizziness, transient renal and hepatic effects, seizures.

How is SUPRAX supplied?

Tabs—50, 100
Susp 100mg/5mL—50mL, 75mL, 100mL
200mg/5mL—25mL, 37.5mL, 50mL, 75mL, 100mL

Related Disease:

Bronchitis, chronic
Infections, bacterial~systemic antiinfectives

Related Resources

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions